Clinical Trials for Non-Small Cell Lung Cancer

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the combination of amivantamab, an EGFR-MET bispecific antibody, and docetaxel in patients with metastatic NSCLC lacking oncogenic driver mutations, who have progressed on platinum-based chemotherapy and immune checkpoint inhibitors. The study focuses on determining the recommended Phase 2 dose and assessing the treatment's efficacy.

ClinicalTrials.gov ID: NCT06532032

Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the safety and feasibility of combining liver SBRT with the immune checkpoint inhibitor Pembrolizumab, which targets PD-1, in adult patients with metastatic non-small cell lung cancer and liver metastases who are eligible for this immunotherapy.

ClinicalTrials.gov ID: NCT05430009

A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets adult patients with advanced NSCLC harboring ALK, ROS1, and RET gene fusions who have progressed on at least one prior FDA-approved TKI, assessing the combination of the investigational bispecific antibody amivantamab, which targets EGFR and MET receptors, with current TKI therapies to overcome acquired resistance.

ClinicalTrials.gov ID: NCT05845671

CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with stage IV or recurrent NSCLC who have progressed after prior systemic therapy (including PD-1/PD-L1 inhibitors) and lack EGFR, ALK, or ROS1 mutations, to receive atezolizumab (PD-L1 inhibitor) plus pirfenidone, an antifibrotic agent with immunomodulatory properties. Suitable patients should have adequate organ function, ECOG 0-2, and no significant comorbidities or prior severe pneumonitis.

ClinicalTrials.gov ID: NCT04467723

Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with stage III NSCLC who have oligoprogressive (≤3 lesions) or polyprogressive (>3 lesions) disease after prior chemoradiation and anti-PD-L1 therapy, treating them with local consolidative therapy (radiation and/or surgery) plus durvalumab (an anti-PD-L1 antibody), with polyprogressive patients also receiving platinum-based chemotherapy. Patients with EGFR or ALK alterations and standard targeted options are excluded.

ClinicalTrials.gov ID: NCT04892953

TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with stage IV non-squamous NSCLC who have either a sensitizing EGFR exon 19 or 21 mutation (after progressing on TKI therapy) or never smokers with wild-type tumors and randomizes them to standard carboplatin, pemetrexed, and bevacizumab with or without atezolizumab, a PD-L1 immune checkpoint inhibitor. Maintenance therapy consists of pemetrexed and bevacizumab, with or without atezolizumab per treatment arm.

ClinicalTrials.gov ID: NCT03786692

A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant CfDNA in Plasma After Initiation of Osimertinib

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Eligible patients are adults with metastatic non-small cell lung cancer harboring activating EGFR mutations who have persistent EGFR-mutant ctDNA in plasma after initial osimertinib treatment. The trial compares continuation of osimertinib (a third-generation irreversible EGFR TKI) alone versus osimertinib combined with carboplatin and pemetrexed chemotherapy.

ClinicalTrials.gov ID: NCT04410796

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This trial enrolls adults with advanced, EGFR-mutated non-squamous NSCLC—either after progression on prior EGFR TKI therapy or with persistent mutant ctDNA on front-line osimertinib—to receive a combination of osimertinib and carotuximab, a monoclonal antibody targeting endoglin (CD105) to inhibit tumor angiogenesis. Eligible patients may have stable or treated brain metastases and must have measurable disease and available tumor tissue or willingness to undergo biopsy.

ClinicalTrials.gov ID: NCT05401110

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with untreated, unresectable, locally advanced or metastatic non-squamous NSCLC harboring HER2 exon 19 or 20 mutations and randomizes them to trastuzumab deruxtecan—an antibody-drug conjugate targeting HER2—or standard platinum chemotherapy with pembrolizumab and pemetrexed. Eligible patients must have ECOG performance status 0-1 and be candidates for systemic therapy.

ClinicalTrials.gov ID: NCT05048797

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with stage IV or recurrent NSCLC harboring EGFR, ALK, ROS1, or HER2 alterations, who have progressed after appropriate targeted and systemic therapy (excluding prior PD-1/PD-L1 inhibitors). Patients receive CD40L-augmented tumor-infiltrating lymphocytes (TILs), which are designed to enhance T-cell activation, in combination with nivolumab following lymphodepleting chemotherapy and interleukin-2 support.

ClinicalTrials.gov ID: NCT05681780